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Increased CD200 expression in acute myeloid leukemia is linked
with an increased frequency of FoxP3þ regulatory T cells
Leukemia (2012) 26, 2146–2148; doi:10.1038/leu.2012.75
CD200 is a type-1a transmembrane cell-surface glycoprotein that
is normally expressed in critical tissues such as the central nervous
system and testis, as well as certain leukocytes, including T and B
lymphocytes, where its role is to promote peripheral tolerance
and protect immune privileged sites.1 CD200 has no known
intracellular signaling motif, but induces immunosuppression
through engagement with CD200R, a cell-surface receptor
homolog, which is expressed on leukocytes of myeloid lineage,
including mast-cells, macrophages, basophils, dendritic cells as
well as certain T-cell populations.2 CD200, which is frequently
overexpressed in acute myeloid leukemia (AML) patient blasts and
associated with a worse outcome,3 has the potential to induce the
formation of CD4þCD25þþFoxP3þ regulatory T cells (Tregs),4
a subset of immunosuppressive T cells that are linked with a
poor prognosis in AML.5 Most importantly, Tregs have been
documented to suppress the anti-leukemia response in vitro from
AML patients,6 suggesting that these cells have an important
role in regulating AML patient tumor immunity. We therefore
investigated whether CD200 protein expression on human AML
blasts was associated with an increased frequency of Treg cells in
AML using a cohort of 40 AML patients (at the point of diagnosis
before to any treatment; Supplementary Table S1 for patient
demographic). AML blast CD200 protein expression and patient
Treg frequency was analyzed by ﬂow cytometry (for full gating
strategy, refer to Supplementary Figure S1). The data show that
CD200 blast expression level correlated signiﬁcantly with the
frequency of Treg cells (Figure 1a). This association was found to
be independent of white blood cell count (Figure 1b), suggesting
that CD200 expression on AML blasts promotes Treg formation.
We also examined whether CD200 expression was differentially
expressed on AML blasts with a putative leukemic stem cell
phenotype (CD34þCD38 ),7 but could ﬁnd no evidence for this
within the six samples examined (Supplementary Figure S2).
Given that the depletion of Tregs has been shown to improve
T-cell-mediated therapy, as well as improving antitumor activity
in leukemia patients that are in complete remission;8,9 we
investigated whether Tregs from CD200hi patients were
functionally immunosuppressive. We examined the ability of
puriﬁed Tregs to suppress naı¨ve responder T-cell (CD4þCD25 )
proliferation following CD3/CD28 co-stimulation (refer to
Supplementary Materials and Methods). The data demonstrate
that Tregs isolated from CD200hi AML patients were capable of
suppressing T-cell proliferation at responder to Treg ratios of 41
to 0.01 (Figure 1c). Reciprocal analysis of Tregs from CD200lo
patients could not be carried out because of the extremely low
frequencies of these cells in CD200lo patients (Figure 1d). In fact,
Treg frequencies in CD200lo AML patients were uniformly lower
than in healthy donor controls, suggesting that CD200 has an
inﬂuence on Treg induction in this context.
Since mouse models have suggested that CD200-induced
Tregs are likely to mediate Th1 immunosuppression,10 a cytokine
response with a prognostic link in leukemia,11 we measured the
Th1 cytokine response (TNFa, IL2 and IFNg production) in
CD200hi patients before and after Treg depletion. Representative
ﬂow cytometric plots conﬁrmed Treg depletion using magnetic
separation (Figure 2a). However, removal of Tregs alone was insufﬁ-
cient to signiﬁcantly improve the Th1 cytokine response as detected
by intracellular cytokine staining (Figure 2b). Elsewhere we report that,
in addition to its known inﬂuence on Treg production, CD200 is also
directly immunosuppressive through engagement with CD200R
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on T cells in AML.12 However, in the present study we show that
removal of Treg cells alone is unlikely to show effect in these assays
when large numbers of CD200þ blast cells are present. These data
would predict that Tregs have little impact on immunosuppression
at diagnosis when the disease burden is high, as the dominant
mode of T-cell suppression would be mediated by CD200hi blasts
directly inhibiting Th1 responses.12 Conversely, following chemo-
therapy, the reduction of tumor burden would be predicted to
make Treg-mediated immunosuppression cells the dominant factor.
In summary, these ﬁndings illustrate a clear correlation between
blast CD200 expression level and the frequency of immuno-
suppressive Treg cells. Previous studies of human AML have also
reported increased frequencies of Tregs in untreated disease13 as
well as during regeneration following treatment,14 however, the
link with CD200 expression has not previously been established.
Our data also indicate that while Tregs in these patients may
be functionally immunosuppressive, they may only become
inﬂuential following cytoreduction. Indeed, several studies have
identiﬁed that increased frequencies of Tregs are associated with
relapse in myeloid malignancy.15,16 Furthermore, phase-I
studies using anti-CD200 monoclonal antibody immunotherapy
have shown that blocking CD200 is sufﬁcient to reduce the
Treg frequency in chronic lymphocytic leukemia patients,17
illustrating that blocking CD200 may be therapeutically
advantageous in AML.
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Figure 1. Assessment of AML blast CD200 expression with respect to
Treg frequency and function. Treg cells from 40 AML patients at diagnosis
were identified by flow cytometry based on the frequency of CD3þ
CD4þCD25þþ T cells that were495% FoxP3þ (refer to Supplementary
Figure S1). (a) Linear regression analysis comparing AML blast CD200
expression level with the frequency of Tregs from 40 diagnostic AML
samples. (b) Correlation of AML blast frequency with Treg cell frequency.
To assess the suppressive function, Tregs and naı¨ve T cells (CD4þCD25 )
were isolated from CD200hi AML patients by magnetic separation and
added together at increasing ratios before CD3/CD28 co-stimulation.
Suppression was measured by the ability of Tregs to inhibit naı¨ve
CD4þ T-cell proliferation (refer to Supplementary Materials and
Methods). (c) Suppression of naı¨ve CD4þ T-cell proliferation by AML
Treg cells at indicated Treg to responder ratios (data represent
mean±1 s.d., n¼ 4). (d) Treg cell frequency stratified with respect to
AML blast CD200 expression. *Po0.05 and **Po0.01 analyzed by
one-way analysis of variance with Tukey’s multiple comparison test.
Figure 2. Assessment of AML patient Treg depletion in recovering
the Th1 response in CD200hi patients. Tregs cells were depleted from
CD200hi AML patients by magnetic separation. (a) Representative
flow cytometric data depicting T cells (i) before depletion of Tregs
(CD3þCD4þCD25þþFoxP3þ ) and (ii) following Treg depletion from a
CD200hi AML patient. AML cells were stimulated with PMA/ionomycin
for 6 h at 37 1C before intracellular Th1 cytokine staining was
performed. Flow cytometry was used to assess Th1 cytokine levels
within the CD45þþCD3þCD4þ fraction. (b) Summary data showing
the Th1 response from CD200hi AML patients±Treg cells (n¼ 6).
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Expression of CD200 on AML blasts directly suppresses memory
T-cell function
Leukemia (2012) 26, 2148–2151; doi:10.1038/leu.2012.77
Previous studies have shown that immunosuppression in acute
myeloid leukemia (AML) is associated with changes in the
adaptive immune compartment. Such changes include the
suppression of memory T-cell function1 and the suppression of
Th1 cytokine (TNFa, IL-2 and IFNg)-producing cells.2 A suppressed
immune response in AML is associated with a worse patient
outcome and increased risk of relapse,3 as well as increased risk of
infection impairing patient recovery.4 The over-expression of the
immunosuppressive ligand CD200 is also associated with an
increased risk of relapse in AML (hazard ratio 1.7); an observation
consistent with a hypothesis in which CD200 inhibits clearance of
residual disease.5,6 As memory T-cell responses are central for
tumor immunosurveillance and contribute to prolonged
molecular remission,7 we carried out this study to establish how
these responses were affected in AML patients over-expressing
CD200 (Supplemental Table S1). We initially investigated whether
CD200 expression on AML blasts inﬂuenced CD8þ T-cell cytotoxic
potential and the frequency of TNFa-, IL-2- and IFNg-producing
CD4þ /CD8þ memory T-cells (Supplementary Materials and
Methods and Supplemental Figure S1 for gating strategy). Using
CD107a as a marker of cytotoxic function, AML cells were
activated with PMA/ionomycin. We show that the frequency of
CD107aþCD8þ memory T-cells was signiﬁcantly reduced by
B50% for CD200hi patients when compared with CD200lo AML,
demonstrating that cytotoxic memory T-cell activity was
compromised in CD200hi patients (Figure 1a). Furthermore, the
frequencies of TNFa-, IL-2- and IFNg-producing CD4þ memory
cells were also reduced by B50% for CD200hi patients when
compared with CD200lo AML (Figure 1b), signiﬁcantly so in the
case of IL-2 and IFNg. Interestingly, CD200lo patients displayed a
higher IFNg response, not only with respect to CD200hi patients
but also in comparison to healthy donors, suggesting a role for
this cytokine in AML, which is attenuated by CD200. No difference
was observed for TNFa-, IL-2- and IFNg-producing CD8þ memory
cells between CD200hi, CD200lo and healthy donors (data not
shown). CD200 has also been reported to mediate suppression of
the Th1 response in chronic lymphocytic leukemia as well as solid
tumors,8,9 suggesting that CD200-mediated Th1 suppression is a
central mechanism in cancer immunomodulation.
The ability to simultaneously produce TNFa, IL-2 and IFNg is
an important indicator of ‘T-cell quality’ in anti-tumor/viral
responses.10 We therefore simultaneously measured the
production of all these cytokines in CD200hi and CD200lo
patients after PMA/ionomycin stimulation (Supplemental Figure S1).
A signiﬁcant reduction (30%) in CD4þ memory T-cells capable of
simultaneously producing TNFa, IL-2 and IFNg was observed in
CD200hi compared with CD200lo AML patients (Figure 1c).
Although a similar reduction was observed within the CD8þ
memory cells, the changes in this subpopulation were less
consistent and were not statistically signiﬁcant (Supplemental
Figure S2). To assess if CD200 expression on AML blasts inﬂuences
the memory Th1 response through an antigen-speciﬁc mechan-
ism, we compared T-cell responses with common microbial recall
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